A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery (TroFuse-012)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (TroFuse-010)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (CAMBRIA-2)
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
LEE CHEEN LENG
CONTACT
SC: Nur Rasyidah Muhammad
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Ngu Ming Ruey
CONTACT
SC: Nur Haziqah Binti Mesran
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
TEH HOOI LAY
CONTACT
SC: Sri Ratha Balakrishnan
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
IZZATI BINTI WAN MAHARUDDIN
CONTACT
SC: Nur Syaza Mirza Omar
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
ADLINDA ALIP
CONTACT
SC: Hanisya
Contact no: 03-79492120
A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in hormone receptor-positive and human epidermal growth factor receptor 2-negative locally advanced, unresectable or metastatic breast cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
SC: Ahmad Syarif Bin Ibrahim
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
WONG YOKE FUI, Florence
CONTACT
SC: Hidayati Binti Mohd Sha’ari
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
drazura@beaconhospital.com.my
+603- 77872830
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Ngu Ming Ruey
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
CONTACT
SC: Fong Yian Ching
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
VAISHNAVI A/P JEYASINGAM
CONTACT
SC: Anis Amira Aznan
Subtype: HR-Positive & HER2-negative
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
Phase III, Line of treatment: 2nd &3rd Line , Failed endocrine therapy for chemotherapy candidate , PDL1-positive
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
DR NUR FADHLINA ABDUL SATAR
fadhlinas@ummc.edu.my
CONTACT
SC: Kimee Ku 03-79492120 (Research Room)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Dr Eznal Izwadi Mohd Mahidin
eznal.mahidin@gmail.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /
crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Tan Ai Lian
ailian.tan@gmail.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com, crcsghkuching@gmail.com (Email)
CLICK HERE (Facebook)
Subtype: HR-Negative & HER2-negative (Triple Negative)
A Phase 3 Randomized, Open-Label Study Of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Phase III
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Assoc Prof Dr Rozita Abdul Malik
CONTACT
SC: Toh Yok Yong
Contact: 03-79492120
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
CONTACT
SC: Suntari
Contact: 03-77860845
drazura@beaconhospital.com.my
Institut Kanser Negara
PRINCIPAL INVESTIGATOR
Norhidayu Binti Salimin
ayumin23@gmail.com
CONTACT
SC: Erda Syerena Rosli
erdasyerena@clinicalresearch.my
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
YUSRA BINTI HADI
CONTACT
SC: Nur Fatin Nabilah Ngu Binti Nur Hisyamuddin Ngun
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Choong Swee Hsia
shchoong83@gmail.com
CONTACT
SC: Nur Adilah Binti Abdul Aziz
nuradilah@clinicalresearch.my
Hospital Raja Permaisuri Bainun
PRINCIPAL INVESTIGATOR
Dr Angel Khor Nee Kwan
drangelkwan@gmail.com
CONTACT
SC: Revathe Rajendran
revathe@clinicalresearch.my
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (CAMBRIA-1)
Hospital Wanita dan Kanak-Kanak Sabah
PRINCIPAL INVESTIGATOR
FLORA CHONG LI TZE
CONTACT
Nancy Nuau
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
SOO HOO HWOEI FEN
CONTACT
Nur Rasyidah Muhammad
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Ngu Ming Ruey
CONTACT
Tan Boon Sin
Sultan Ismail Hospital
PRINCIPAL INVESTIGATOR
LIM CHUN SEN
CONTACT
Sri Ratha Balakrishnan
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (TROPION-Breast04)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Adlinda Alip
CONTACT
SC: Haniesya
General line:03-79492120